The Manufacturers Life Insurance Company decreased its position in Sanofi (NYSE:SNY) by 5.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 576,235 shares of the company’s stock after selling 32,042 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Sanofi were worth $28,910,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of SNY. FMR LLC grew its holdings in shares of Sanofi by 19.3% in the 2nd quarter. FMR LLC now owns 21,450,971 shares of the company’s stock worth $1,095,072,000 after purchasing an additional 3,464,099 shares during the last quarter. Fisher Asset Management LLC lifted its position in Sanofi by 2.8% during the 2nd quarter. Fisher Asset Management LLC now owns 18,155,655 shares of the company’s stock worth $926,846,000 after buying an additional 493,628 shares in the last quarter. Clark Capital Management Group Inc. acquired a new position in Sanofi during the 2nd quarter worth about $24,614,000. Morgan Stanley lifted its position in Sanofi by 9.8% during the 1st quarter. Morgan Stanley now owns 5,142,760 shares of the company’s stock worth $224,842,000 after buying an additional 460,930 shares in the last quarter. Finally, GWM Advisors LLC lifted its position in Sanofi by 2,339.6% during the 2nd quarter. GWM Advisors LLC now owns 345,294 shares of the company’s stock worth $17,627,000 after buying an additional 331,140 shares in the last quarter. 7.04% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE SNY opened at $50.52 on Friday. Sanofi has a 52 week low of $37.62 and a 52 week high of $55.00. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The stock’s fifty day moving average is $49.59 and its 200 day moving average is $50.36. The stock has a market capitalization of $126.51 billion, a P/E ratio of 16.14, a PEG ratio of 2.41 and a beta of 0.67.
Several brokerages recently issued reports on SNY. SVB Leerink downgraded shares of Sanofi to a “market perform” rating in a research report on Tuesday, August 18th. Berenberg Bank initiated coverage on shares of Sanofi in a research report on Tuesday, September 29th. They set a “hold” rating on the stock. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Sunday, October 4th. They set a “buy” rating on the stock. Stifel Nicolaus downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $53.00 target price for the company in a research note on Monday, October 19th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $55.67.
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.
Read More: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.